We understand that people with cancer are worried about coronavirus. Here is the latest guidance. We will update it regularly.

Publication Details

Need to talk? Call us free*
0800 808 00 00 Monday to Friday, 9am-8pm
Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer. Information for the public

Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer. Information for the public (January 2020)

Information about palbociclib (Ibrance), with fulvestrant, which is available through the Cancer Drugs Fund, and which may be used to treat hormone receptor-positive, HER2-negative, advanced breast cancer.

Author(s)
National Institute for Health and Care Excellence (NICE)
Place of publication
London
Date of publication
January 2020
Pages
2pp
Series
Technology appraisal guidance
Price
Free.
Format
Factsheet
Language
English
Download this resource
Need to talk? Call us free*
0800 808 00 00 Monday to Friday, 9am-8pm